Incorporation of the aperture thickness in proton pencil-beam dose calculations

Implementation of apertures in a proton pencil-beam dose algorithm

The use of field-specific apertures, routine in scattered or uniform-scanned proton fields, are still a necessity in pencil-beam scanned (PBS) fields to sharpen the penumbral edge at low energies and in high fraction dose application beyond that achievable with small spot size. We describe a model implemented in our clinical pencil-beam algorithm that models the insertion of a shaped aperture, including shapes adapted per energy layer such as may be achieved with a multi-leaf collimator. The model decomposes the spot transport into discrete steps. The first step transport a uniform intensity field of high-resolution sub-pencil-beams at the layer energy through the medium. This transport only considers primary scattering in both the patient and an optional range-shifter. The second step models the aperture areas and edge penumbral transition as a modulation of the uniform intensity. The third step convolves individual steps over the uniform-transported field including the aperture-modified intensities. We also introduce an efficient model based on a Clarkson sector integration for nuclear scattered halo protons. This avoids the explicit modeling of long range halo protons to the detriment of computational efficiency in calculation and optimization. We demonstrate that the aperture effect is primarily due to in-patient and shifter scattering with a small contribution from the apparent beam source position. The model provides insight into the primary physics contributions to the penumbra and the nuclear halo. The model allowed us to fully deploy our PBS capacity at our two-gantry center without which PBS treatments would have been inferior compared to scattered fields with apertures. Finally, Monte Carlo calculations have (nearly) replaced phenomenological pencil-beam models for collimated fields. Phenomenological models do, however, allow exposition of underlying clinical phenomena and closer connection to representative clinical observables.

Characterization of the HollandPTC proton therapy beamline dedicated to uveal melanoma treatment and an interinstitutional comparison

PURPOSE

Eye-dedicated proton therapy (PT) facilities are used to treat malignant intraocular lesions, especially uveal melanoma (UM). The first commercial ocular PT beamline from Varian was installed in the Netherlands. In this work, the conceptual design of the new eyeline is presented. In addition, a comprehensive comparison against five PT centers with dedicated ocular beamlines is performed, and the clinical impact of the identified differences is analyzed.

MATERIAL/METHODS

The HollandPTC eyeline was characterized. Four centers in Europe and one in the United States joined the study. All centers use a cyclotron for proton beam generation and an eye-dedicated nozzle. Differences among the chosen ocular beamlines were in the design of the nozzle, nominal energy, and energy spectrum. The following parameters were collected for all centers: technical characteristics and a set of distal, proximal, and lateral region measurements. The measurements were performed with detectors available in-house at each institution. The institutions followed the International Atomic Energy Agency (IAEA) Technical Report Series (TRS)-398 Code of Practice for absolute dose measurement, and the IAEA TRS-398 Code of Practice, its modified version or International Commission on Radiation Units and Measurements Report No. 78 for spread-out Bragg peak normalization. Energy spreads of the pristine Bragg peaks were obtained with Monte Carlo simulations using Geant4. Seven tumor-specific case scenarios were simulated to evaluate the clinical impact among centers: small, medium, and large UM, located either anteriorly, at the equator, or posteriorly within the eye. Differences in the depth dose distributions were calculated.

RESULTS

A pristine Bragg peak of HollandPTC eyeline corresponded to the constant energy of 75 MeV (maximal range 3.97 g/cm2 in water) with an energy spread of 1.10 MeV. The pristine Bragg peaks for the five participating centers varied from 62.50 to 104.50 MeV with an energy spread variation between 0.10 and 0.70 MeV. Differences in the average distal fall-offs and lateral penumbrae (LPs) (over the complete set of clinically available beam modulations) among all centers were up to 0.25 g/cm2 , and 0.80 mm, respectively. Average distal fall-offs of the HollandPTC eyeline were 0.20 g/cm2 , and LPs were between 1.50 and 2.15 mm from proximal to distal regions, respectively. Treatment time, around 60 s, was comparable among all centers. The virtual source-to-axis distance of 120 cm at HollandPTC was shorter than for the five participating centers (range: 165-350 cm). Simulated depth dose distributions demonstrated the impact of the different beamline characteristics among institutions. The largest difference was observed for a small UM located at the posterior pole, where a proximal dose between two extreme centers was up to 20%.

CONCLUSIONS

HollandPTC eyeline specifications are in accordance with five other ocular PT beamlines. Similar clinical concepts can be applied to expect the same high local tumor control. Dosimetrical properties among the six institutions induce most likely differences in ocular radiation-related toxicities. This interinstitutional comparison could support further research on ocular post-PT complications. Finally, the findings reported in this study could be used to define dosimetrical guidelines for ocular PT to unify the concepts among institutions.

TOPAS Monte Carlo simulation for double scattering proton therapy and dosimetric evaluation

PURPOSE

To construct and commission a double scattering (DS) proton beam model in TOPAS Monte Carlo (MC) code. Dose comparisons of MC calculations to the measured and treatment planning system (TPS) calculated dose were performed.

METHODS

The TOPAS nozzle model was based on the manufacturer blueprints. Nozzle set-up and beam current modulations were calculated using room-specific calibration data. This model was implemented to reproduce pristine peaks, spread-out Bragg peaks (SOBP) and lateral profiles. A stair-shaped target plan in water phantom was calculated and compared to measured data to verify range compensator (RC) modeling.

RESULTS

TOPAS calculated pristine peaks agreed well with measurements, with accuracies of 0.03 cm for range R₉₀ and 0.05 cm for distal dose fall-off (DDF). The calculated SOBP range, modulation width and DDF differences between MC calculations and measurements were within 0.05 cm, 0.5 cm and 0.03 cm respectively. MC calculated lateral penumbra agreed well with measured data, with difference less than 0.05 cm. For RC calculation, TPS underestimated the additional depth dose tail due to the nuclear halo effect. Lateral doses by TPS were 10% lower than measurement outside the target, while maximum difference of MC calculation was within 2%. At deeper depths inside the target volume, TPS overestimated doses by up to 25% while TOPAS predicted the dose to within 5% of measurements.

CONCLUSION

We have successfully developed and commissioned a MC based DS nozzle model. The performance of dose accuracy by TOPAS was superior to TPS, especially for highly inhomogeneous compensator.

A REVIEW OF ANALYTICAL MODELS OF STRAY RADIATION EXPOSURES FROM PHOTON- AND PROTON-BEAM RADIOTHERAPIES

External-beam radiation therapy is safe, effective and widely used to treat cancer. With 5-year cancer survival for adults above 70%, increasingly research is focusing on quantifying and reducing treatment-related morbidity. Reducing exposures to healthy tissues is one strategy, which can be accomplished with advanced-technology radiotherapies, such as intensity-modulated photon therapy and proton therapy. Both of these modalities provide good conformation of the therapeutic dose to the tumor volume, but they also deliver stray radiation to the whole body that increases the risk of radiogenic second cancers. To minimize these risks, one needs to create and compare candidate treatment plans that explicitly take into account these risks. Currently, clinical practice does not include routine calculation of stray radiation exposure and, consequently, the assessment of corresponding risks is difficult. In this article, we review recent progress toward stray dose algorithms that are suitable for large-scale clinical use. In particular, we emphasize the current state of physics-based dose algorithms for intensity-modulated photon radiotherapy and proton therapy.

Outcomes of Sinonasal Cancer Treated With Proton Therapy

PURPOSE

To report disease outcomes after proton therapy (PT) for sinonasal cancer.

METHODS AND MATERIALS

Eighty-four adult patients without metastases received primary (13%) or adjuvant (87%) PT for sinonasal cancers (excluding melanoma, sarcoma, and lymphoma). Common histologies were olfactory neuroblastoma (23%), squamous cell carcinoma (22%), and adenoid cystic carcinoma (17%). Advanced stage (T3 in 25% and T4 in 69%) and high-grade histology (51%) were common. Surgical procedures included endoscopic resection alone (45%), endoscopic resection with craniotomy (12%), or open resection (30%). Gross residual disease was present in 26% of patients. Most patients received hyperfractionated PT (1.2 Gy [relative biological effectiveness (RBE)] twice daily, 99%) and chemotherapy (75%). The median PT dose was 73.8 Gy (RBE), with 85% of patients receiving more than 70 Gy (RBE). Prognostic factors were analyzed using Kaplan-Meier analysis and proportional hazards regression for multiple regression. Dosimetric parameters were evaluated using logistic regression. Serious, late grade 3 or higher toxicity was reported using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4. The median follow-up was 2.4 years for all patients and 2.7 years among living patients.

RESULTS

The local control (LC), neck control, freedom from distant metastasis, disease-free survival, cause-specific survival, and overall survival rates were 83%, 94%, 73%, 63%, 70%, and 68%, respectively, at 3 years. Gross total resection and PT resulted in a 90% 3-year LC rate. The 3-year LC rate was 61% for primary radiation therapy and 59% for patients with gross disease. Gross disease was the only significant factor for LC on multivariate analysis, whereas grade and continuous LC were prognostic for overall survival. Six of 12 local recurrences were marginal. Dural dissemination represented 26% of distant recurrences. Late toxicity occurred in 24% of patients (with grade 3 or higher unilateral vision loss in 2%).

CONCLUSIONS

Dose-intensified, hyperfractionated PT with or without concurrent chemotherapy results in excellent LC after gross total resection, and results in patients with gross disease are encouraging. Patients with high-grade histology are at greater risk of death from distant dissemination. Continuous LC is a major determinant of survival justifying aggressive local therapy in nearly all cases.

An empirical model for calculation of the collimator contamination dose in therapeutic proton beams

Collimators are used as lateral beam shaping devices in proton therapy with passive scattering beam lines. The dose contamination due to collimator scattering can be as high as 10% of the maximum dose and influences calculation of the output factor or monitor units (MU). To date, commercial treatment planning systems generally use a zero-thickness collimator approximation ignoring edge scattering in the aperture collimator and few analytical models have been proposed to take scattering effects into account, mainly limited to the inner collimator face component. The aim of this study was to characterize and model aperture contamination by means of a fast and accurate analytical model. The entrance face collimator scatter distribution was modeled as a 3D secondary dose source. Predicted dose contaminations were compared to measurements and Monte Carlo simulations. Measurements were performed on two different proton beam lines (a fixed horizontal beam line and a gantry beam line) with divergent apertures and for several field sizes and energies. Discrepancies between analytical algorithm dose prediction and measurements were decreased from 10% to 2% using the proposed model. Gamma-index (2%/1 mm) was respected for more than 90% of pixels. The proposed analytical algorithm increases the accuracy of analytical dose calculations with reasonable computation times.

Use of diverging apertures to minimize the edge scatter in passive scattering proton therapy

The purpose of this study was to evaluate the use of diverging-cut aperture to minimize collimator contamination in proton therapy. Two sets of apertures with nondivergent and divergent edge were fabricated to produce a 10 cm × 10 cm field at the radiation isocenter of a single-room proton therapy unit. Transverse profiles were acquired in a scanning water tank with both aperture sets. Up to 9.5% extra dose was observed from aperture scattering near the field edges with the nondivergent aperture set at 2 cm above the water surface and remained 3.0% at depth of 10 cm. For the divergent set, the contamination was reduced to less than 3.5% and 1.3%, respectively. Our study demonstrated that scattering from apertures contaminated the dose distribution near the field edge at shallow depth. A diverging-cut aperture was capable of reducing the contamination and is recommended for use in passive scattering proton therapy, especially when critical organs are lateral and proximal to the target at shallow depth.

Semi-analytical model for output factor calculations in proton beam therapy with consideration for the collimator aperture edge

In the development of an external radiotherapy treatment planning system, the output factor (OPF) is an important value for the monitor unit calculations. We developed a proton OPF calculation model with consideration for the collimator aperture edge to account for the dependence of the OPF on the collimator aperture and distance in proton beam therapy. Five parameters in the model were obtained by fitting with OPFs measured by a pinpoint chamber with the circular radiation fields of various field radii and collimator distances. The OPF model calculation using the fitted model parameters could explain the measurement results to within 1.6% error in typical proton treatment beams with 6- and 12 cm SOBP widths through a range shifter and a circular aperture more than 10.6 mm in radius. The calibration depth dependences of the model parameters were approximated by linear or quadratic functions. The semi-analytical OPF model calculation was tested with various MLC aperture shapes that included circles of various sizes as well as a rectangle, parallelogram, and L-shape for an intermediate proton treatment beam condition. The pre-calculated OPFs agreed well with the measured values, to within 2.7% error up to 620 mm in the collimator distance, though the maximum difference was 5.1% in the case of the largest collimator distance of 740 mm. The OPF calculation model would allow more accurate monitor unit calculations for therapeutic proton beams within the expected range of collimator conditions in clinical use.

Reduction of the secondary neutron dose in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator

Proton radiotherapy represents a potential major advance in cancer therapy. Most current proton beams are spread out to cover the tumor using passive scattering and collimation, resulting in an extra whole-body high-energy neutron dose, primarily from proton interactions with the final collimator. There is considerable uncertainty as to the carcinogenic potential of low doses of high-energy neutrons, and thus we investigate whether this neutron dose can be significantly reduced without major modifications to passively scattered proton beam lines. Our goal is to optimize the design features of a patient-specific collimator or pre-collimator/collimator assembly. There are a number of often contradictory design features, in terms of geometry and material, involved in an optimal design. For example, plastic or hybrid plastic/metal collimators have a number of advantages. We quantify these design issues, and investigate the practical balances that can be achieved to significantly reduce the neutron dose without major alterations to the beamline design or function. Given that the majority of proton therapy treatments, at least for the next few years, will use passive scattering techniques, reducing the associated neutron-related risks by simple modifications of the collimator assembly design is a desirable goal.

Parametrization and application of scatter kernels for modelling scanned proton beam collimator scatter dose

Collimators are routinely used in proton radiotherapy to laterally confine the field and improve the penumbra. Collimator scatter contributes up to 15% of the local dose and is therefore important to include in treatment planning dose calculation. We present a method for reconstruction of the collimator scatter phase space based on the parametrization of pre-calculated scatter kernels. Collimator scatter distributions, generated by the Monte Carlo (MC) package GEANT4.8.2, were scored differential in direction and energy. The distributions were then parametrized so as to enable a fast reconstruction by sampling. MC calculated dose distributions in water based on the parametrized phase space were compared to full MC simulations that included the collimator in the simulation geometry, as well as to experimental data. The experiments were performed at the scanned proton beam line at the The Svedberg Laboratory (TSL) in Uppsala, Sweden. Dose calculations using the parametrization of this work and the full MC for isolated typical cases of collimator scatter were compared by means of the gamma index. The result showed that in total 96.7% (99.3%) of the voxels fulfilled the gamma 2.0%/2.0 mm (3.0%/3.0 mm) criterion. The dose distribution for a collimated field was calculated based on the phase space created by the collimator scatter model incorporated into the generation of the phase space of a scanned proton beam. Comparing these dose distributions to full MC simulations, including particle transport in the MLC, yielded that in total for 18 different collimated fields, 99.1% of the voxels satisfied the gamma 1.0%/1.0 mm criterion and no voxel exceeded the gamma 2.6%/2.6 mm criterion. The dose contribution of collimator scatter along the central axis as predicted by the model showed good agreement with experimental data.

Experimental test of Monte Carlo proton transport at grazing incidence in GEANT4, FLUKA and MCNPX

The ability of the Monte Carlo (MC) particle transport codes GEANT4.8.1 and GEANT4.8.2, FLUKA2006 and MCNPX2.4.0 to model proton transport at grazing incidence onto tungsten blocks has been tested and compared to experimental measurements. The test geometry consisted of a narrow proton beam of two energies, 98 MeV and 180 MeV, impinging on a thick tungsten alloy block at grazing incidence. The distribution of forward out-scatter from the tungsten alloy block was measured with a fluorescent screen viewed with a CCD camera via a mirror. In the MC simulations, the experimental setup was modelled and the dose deposited to the fluorescent screen material was scored. Simulations and measurements were made for four different incidence angles (3.5, 5.0, 7.5 and 10 degrees ). Several different sets of calculations were performed, studying the impact of different user-defined settings in the different MC packages. The study of different parameters settings in the GEANT4.8.1 simulation showed a strong dependence of the calculated out-scatter probability on the maximum allowed step length. For the largest incidence angle an increase of 60% in the out-scatter probability was found when restricting the maximum allowed step length to 0.05 cm. We also observed that the stepping algorithm of GEANT4.8.1 and 4.8.2 introduces a small non-physical directional and positional asymmetry at the exit boundary of the tungsten alloy block. The shape of the energy spectrum of protons being out-scattered agreed between the codes. The dose-weighted forward out-scatter probability, i.e. the ratio between the total signal from the unscattered beam and the out-scattered beam, showed a qualitative agreement of simulations compared to measurements. Quantitatively, the deviation of the simulations reached as high as 37%, while the experimental uncertainty was 14%. The mean emission angle of the simulations was within 16% of the measurement for all incidence angles with a measurement uncertainty of 8%.

Monte Carlo investigation of collimator scatter of proton-therapy beams produced using the passive scattering method

As a proton-therapy beam passes through the field-limiting aperture, some of the protons are scattered off the edges of the collimator. The edge-scattered protons can degrade the dose distribution in a patient or phantom, and these effects are difficult to model with analytical methods such as those available in treatment planning systems. The objective of this work was to quantify the dosimetric impact of edge-scattered protons for a representative variety of clinical treatment beams. The dosimetric impact was assessed using Monte Carlo simulations of proton beams from a contemporary treatment facility. The properties of the proton beams were varied, including the penetration range (6.4-28.5 cm), width of the spread-out Bragg peak (SOBP; 2-16 cm), field size (3 x 3 cm(2) to 15 x 15 cm(2)) and air gap, i.e. the distance between the collimator and the phantom (8-48 cm). The simulations revealed that the dosimetric impact of edge-scattered protons increased strongly with increasing range (dose increased by 6-20% with respect to the dose at the center of the spread-out Bragg peak), decreased strongly with increasing field size (dose changed by 2-20%), increased moderately with increasing air gap (dose increased by 2-6%) and increased weakly with increasing SOBP width (dose change <4%). In all cases examined, the effects were largest at shallow depths. We concluded that the dose deposited by edge-scattered protons can distort the dose proximal to the target with varying contributions due to the proton range, treatment field size, collimator position and thickness, and width of the SOBP. Our findings also suggest that accurate predictions of dose per monitor-unit calculations may require taking into account the dose from protons scattered from the edge of the patient-specific collimator, particularly for fields of small lateral size and deep depths.